+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Self-Complementary Adeno-Associated Virus-Mediated Interleukin-1 Receptor Antagonist Gene Delivery for the Treatment of Osteoarthritis: Test of Efficacy in an Equine Model

Self-Complementary Adeno-Associated Virus-Mediated Interleukin-1 Receptor Antagonist Gene Delivery for the Treatment of Osteoarthritis: Test of Efficacy in an Equine Model

Human Gene Therapy. Clinical Development 29(2): 101-112

The authors are investigating self-complementary adeno-associated virus (scAAV) as a vector for intra-articular gene-delivery of interleukin-1 receptor antagonist (IL-1Ra), and its therapeutic capacity in the treatment of osteoarthritis (OA). To model gene transfer on a scale proportional to the human knee, a frequent site of OA incidence, studies were focused on the joints of the equine forelimb. Using AAV2.5 capsid and equine IL-1Ra as a homologous transgene, a functional ceiling dose of ∼5 × 1012 viral genomes was previously identified, which elevated the steady state levels of eqIL-1Ra in synovial fluids by >40-fold over endogenous production for at least 6 months. Here, using an osteochondral fragmentation model of early OA, the functional capacity of scAAV.IL-1Ra gene-delivery was examined in equine joints over a period of 12 weeks. In the disease model, transgenic eqIL-1Ra expression was several fold higher than seen previously in healthy joints, and correlated directly with the severity of joint pathology at the time of treatment. Despite wide variation in expression, the steady-state eqIL-1Ra in synovial fluids exceeded that of IL-1 by >400-fold in all animals, and a consistent treatment effect was observed. This included a 30-40% reduction in lameness and ∼25% improvement in total joint pathology by both magnetic resonance imaging and arthroscopic assessments, which included reduced joint effusion and synovitis, and improved repair of the osteochondral lesion. No vector-related increase in eqIL-1Ra levels in blood or urine was noted. Cumulatively, these studies in the equine model indicate scAAV.IL-1Ra administration is reasonably safe and capable of sustained therapeutic IL-1Ra production intra-articularly in joints of human scale. This profile supports consideration for human testing in OA.

(PDF emailed within 0-6 h: $19.90)

Accession: 065496646

Download citation: RISBibTeXText

PMID: 29869535

DOI: 10.1089/humc.2017.143

Related references

Gene Therapy for Osteoarthritis: Pharmacokinetics of Intra-Articular Self-Complementary Adeno-Associated Virus Interleukin-1 Receptor Antagonist Delivery in an Equine Model. Human Gene Therapy. Clinical Development 29(2): 90-100, 2018

Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Therapy 9(1): 12-20, January, 2002

Evaluation of topical diclofenac liposomal cream for treatment of equine osteoarthritis using an equine experimental model. 2007

ScAAV-mediated gene transfer of interleukin-1-receptor antagonist to synovium and articular cartilage in large mammalian joints. Gene Therapy 20(6): 670-677, 2013

Minicircle Mediated Gene Delivery to Canine and Equine Mesenchymal Stem Cells. International Journal of Molecular Sciences 18(4), 2017

Evaluation of gene therapy as a treatment for equine traumatic arthritis and osteoarthritis. Clinical Orthopaedics and Related Research 2000(379 Suppl): S273-S287, 2000

Survey of the therapeutic approach and efficacy of pentosan polysulfate for the prevention and treatment of equine osteoarthritis in veterinary practice in Australia. Australian Veterinary Journal 92(12): 482-487, 2015

Targeted delivery to cartilage is critical for in vivo efficacy of insulin-like growth factor 1 in a rat model of osteoarthritis. Arthritis and Rheumatology 66(5): 1247-1255, 2014

Protease pretreatment increases the efficacy of adenovirus-mediated gene therapy for the treatment of an experimental glioblastoma model. Cancer Research 61(5): 1805-1809, 2001

Treatment of equine joint diseases. Part 2: Surgical and physical treatment of equine osteoarthritis. UK Vet: Companion Animal 12(8): 10-15, 2007

Evaluation of intra-articular polysulfated glycosaminoglycan and sodium hyaluronan for treatment of osteoarthritis using an equine experimental model. Proceedings Of The 54th Annual Convention Of The American Association Of Equine Practitioners, San Diego, California, Usa, 6-10: 0-251, 2008

Efficacy of a portable oxygen concentrator with pulsed delivery for treatment of hypoxemia during equine field anesthesia. Veterinary Anaesthesia and Analgesia 42(5): 518-526, 2016

Treatment of equine joint diseases. Part 1: Pharmacological management of equine osteoarthritis (OA). UK Vet: Companion Animal 12(4): 9-15, 2007

Adenovirus-mediated gene transfer and lipoprotein-mediated protein delivery of plasma PAF-AH ameliorates proteinuria in rat model of glomerulosclerosis. Molecular Therapy 13(1): 118-126, 2005

Evaluating intra-articular drug delivery for the treatment of osteoarthritis in a rat model. Tissue Engineering. Part B, Reviews 16(1): 81-92, 2010